Search for: "Rachel Sachs" Results 61 - 80 of 155
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
Multi-Agency Funding for COVID-19 Vaccine Development
19 Aug 2020, 10:58 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part II: Allocating Access
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
Written Description - http://writtendescription.blogspot.com/
Multi-Agency Funding for COVID-19 Vaccine Development
19 Aug 2020, 10:58 am by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsModerna, Inc., a Cambridge, MA-based biotech company, is a leading contender in the race to develop a SARS-CoV-2 vaccine. [read post]
Written Description - http://writtendescription.blogspot.com/
Remdesivir Part II: Allocating Access
19 May 2020, 3:30 pm by Lisa Larrimore Ouellette
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
Written Description - http://writtendescription.blogspot.com/
What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?
30 Nov 2020, 7:24 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
IPSC plenary
10 Aug 2018, 5:15 pm by Rebecca Tushnet
  If it surfaces the same relatively unpopular songs for every listener w/in a group, that might matter v. if it randomizes w/in a group of equally unpopular similar songs.]Rachel Sachs, Regulating Intermediate Technologies Health care tech where we want to incentivize improvement of existing tech but we’ve set up the system wrong. [read post]
43(B)log - http://tushnet.blogspot.com/
What are the innovation challenges to scaling vaccine manufacturing?
10 Sep 2020, 6:23 pm by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What can policymakers learn from the UK’s RECOVERY trial to improve clinical research for COVID-19 and beyond?
3 May 2021, 8:36 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers use “pull” mechanisms to improve COVID-19 innovation incentives?
30 Jul 2020, 3:39 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How should policymakers use “pull” mechanisms to improve COVID-19 innovation incentives?
30 Jul 2020, 3:39 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How does pregnancy factor into COVID-19 innovation?
6 Dec 2021, 6:24 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What administrative actions might we expect on COVID-19 in President-elect Biden’s administration?
30 Nov 2020, 7:24 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How does the CDC’s Advisory Committee on Immunization Practices impact innovation and access to COVID-19 vaccines?
27 Aug 2021, 12:18 pm by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How does the law impact the use of 3D printing to address COVID-19 production shortages?
27 Apr 2020, 1:27 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowHealth systems worldwide are facing shortages of crucial medical supplies, including personal protective equipment (PPE), diagnostic testing components including kits and nasal swabs, and even ventilators or ventilator parts. [read post]
Written Description - http://writtendescription.blogspot.com/
Why aren’t therapeutic antibodies being used more to treat COVID-19?
29 Jan 2021, 10:26 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can Congress create infrastructure for the next pandemic?
9 Apr 2021, 8:03 am by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers overcome the hurdles to scaling up antibody manufacturing?
18 Feb 2021, 10:24 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What are the innovation challenges to scaling vaccine manufacturing?
10 Sep 2020, 6:23 pm by Lisa Larrimore Ouellette
By Nicholson Price, Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
What did we learn from last week’s FDA vaccine advisory committee meeting?
30 Oct 2020, 12:50 pm by Lisa Larrimore Ouellette
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/
How can policymakers overcome the hurdles to scaling up antibody manufacturing?
18 Feb 2021, 10:24 am by Lisa Larrimore Ouellette
By Rachel Sachs, Jacob S. [read post]
Written Description - http://writtendescription.blogspot.com/